Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.44 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30985154 | 0.90 | CRBN (0.45) | CRBNDDB1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL30984814 | 0.90 | CRBN (0.46) | CRBNDDB1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL31546718 | 0.87 | CRBN (0.42) | CRBNDDB1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL30984869 | 0.83 | CRBN (0.55) | CRBNDDB1IKZF2CSNK1A1IKZF1 | |
| SCHEMBL20235033 | 0.82 | CRBN (0.56) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL21340251 | 0.81 | IKZF1 (0.55) | CRBNDDB1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL31025907 | 0.80 | CRBN (0.47) | CRBNDDB1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL24572309 | 0.80 | IKZF2 (0.57) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL20234476 | 0.79 | IKZF2 (0.47) | CRBNDDB1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL21759799 | 0.79 | CRBN (0.53) | CRBNDDB1IKZF2CSNK1A1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885DDB1 192/4885IKZF2 1564/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885DDB1 192/4885IKZF2 1564/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885DDB1 192/4885IKZF2 1564/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | CRBN 2/4885DDB1 192/4885IKZF2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.